BU

BUKWANG PHARMACEUTICAL IND CO.,LTD

R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.

003000 | KO

Overview

Corporate Details

ISIN(s):
KR7003000007
LEI:
Country:
South Korea
Address:
서울특별시 동작구 대방동1길 47, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bukwang Pharmaceutical Co., Ltd. is an R&D-focused pharmaceutical company engaged in the development, manufacturing, and commercialization of therapeutic drugs. The company employs an 'open innovation' strategy, utilizing strategic investments, joint ventures, research collaborations, and acquisitions to expand its drug pipeline and enhance its global competitiveness. Its development pipeline targets a range of conditions, with a focus on central nervous system (CNS) disorders such as schizophrenia (Lurasidone) and Parkinson's disease (JM-010), as well as oncology (SOL-804 for prostate cancer), liver diseases, and metabolic disorders. Through continuous research and strategic partnerships, Bukwang aims to become a global pharmaceutical innovator.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 10.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-14 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-07-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-22 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 20.8 KB
2025-07-21 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 21.2 KB
2025-07-16 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 196.6 KB
2025-07-16 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
Korean 8.5 KB
2025-07-16 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-07-15 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시)
Korean 11.3 KB
2025-07-15 00:00
Related Party Transaction
[기재정정]특수관계인의유상증자참여
Korean 12.3 KB
2025-07-10 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시)
Korean 12.1 KB
2025-07-10 00:00
Related Party Transaction
[기재정정]특수관계인의유상증자참여
Korean 12.9 KB

Automate Your Workflow. Get a real-time feed of all BUKWANG PHARMACEUTICAL IND CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BUKWANG PHARMACEUTICAL IND CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BUKWANG PHARMACEUTICAL IND CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA

Talk to a Data Expert

Have a question? We'll get back to you promptly.